Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naim Alkhouri

Showing results (251-260 of 306) with videos related to

Pageof 31
Sort By:
Journal of Hepatology|November 5, 2022
Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASHVlad Ratziu, Stephen A Harrison, Véronique Loustaud-Ratti, et al.
Journal of Gastroenterology and Hepatology|November 22, 2015
The development of a non-invasive model to predict the presence of non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver diseaseGeorge Bb Goh, Danny Issa, Rocio Lopez, et al.
Lancet (London, England)|November 16, 2019
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trialStephen A Harrison, Mustafa R Bashir, Cynthia D Guy, et al.
Hepatology Communications|May 4, 2023
Increased accuracy in identifying NAFLD with advanced fibrosis and cirrhosis: independent validation of the Agile 3+ and 4 scoresMazen Noureddin, Edward Mena, Raj Vuppalanchi, et al.
Hepatology (Baltimore, Md.)|July 9, 2022
Machine learning models are superior to noninvasive tests in identifying clinically significant stages of NAFLD and NAFLD-related cirrhosisDevon Chang, Emily Truong, Edward A Mena, et al.
Alimentary Pharmacology & Therapeutics|June 30, 2020
Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practicesZobair M Younossi, Kathleen E Corey, Naim Alkhouri, et al.
Contemporary Clinical Trials|December 28, 2019
Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study designQuentin M Anstee, Brent A Neuschwander-Tetri, Vincent Wai-Sun Wong, et al.
Hepatology Communications|April 30, 2025
Global patterns of utilization of noninvasive tests for the clinical management of metabolic dysfunction-associated steatotic liver diseaseAlina M Allen, Jeffrey V Lazarus, Naim Alkhouri, et al.
Medicine|July 3, 2019
Real-world observational experience with direct-acting antivirals for hepatitis C: baseline resistance, efficacy, and need for long-term surveillanceNicole Loo, Bryan Hanysak, Jena Mann, et al.
Journal of Pediatric Gastroenterology and Nutrition|January 18, 2011
Relations of steatosis type, grade, and zonality to histological features in pediatric nonalcoholic fatty liver diseaseChristine Carter-Kent, Elizabeth M Brunt, Lisa M Yerian, et al.
Pageof 31

Showing results (251-260 of 306) with videos related to

Sort By:
Pageof 31
Journal of Hepatology|November 5, 2022
Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASHVlad Ratziu, Stephen A Harrison, Véronique Loustaud-Ratti, et al.
Journal of Gastroenterology and Hepatology|November 22, 2015
The development of a non-invasive model to predict the presence of non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver diseaseGeorge Bb Goh, Danny Issa, Rocio Lopez, et al.
Lancet (London, England)|November 16, 2019
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trialStephen A Harrison, Mustafa R Bashir, Cynthia D Guy, et al.
Hepatology Communications|May 4, 2023
Increased accuracy in identifying NAFLD with advanced fibrosis and cirrhosis: independent validation of the Agile 3+ and 4 scoresMazen Noureddin, Edward Mena, Raj Vuppalanchi, et al.
Hepatology (Baltimore, Md.)|July 9, 2022
Machine learning models are superior to noninvasive tests in identifying clinically significant stages of NAFLD and NAFLD-related cirrhosisDevon Chang, Emily Truong, Edward A Mena, et al.
Alimentary Pharmacology & Therapeutics|June 30, 2020
Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practicesZobair M Younossi, Kathleen E Corey, Naim Alkhouri, et al.
Contemporary Clinical Trials|December 28, 2019
Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study designQuentin M Anstee, Brent A Neuschwander-Tetri, Vincent Wai-Sun Wong, et al.
Hepatology Communications|April 30, 2025
Global patterns of utilization of noninvasive tests for the clinical management of metabolic dysfunction-associated steatotic liver diseaseAlina M Allen, Jeffrey V Lazarus, Naim Alkhouri, et al.
Medicine|July 3, 2019
Real-world observational experience with direct-acting antivirals for hepatitis C: baseline resistance, efficacy, and need for long-term surveillanceNicole Loo, Bryan Hanysak, Jena Mann, et al.
Journal of Pediatric Gastroenterology and Nutrition|January 18, 2011
Relations of steatosis type, grade, and zonality to histological features in pediatric nonalcoholic fatty liver diseaseChristine Carter-Kent, Elizabeth M Brunt, Lisa M Yerian, et al.
Pageof 31